Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhifeng Cheng

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Nature|December 17, 2025
Mazdutide versus placebo in Chinese adults with type 2 diabetesDalong Zhu, Jiajun Zhao, Hanqing Cai, et al.
Nature|December 17, 2025
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetesLixin Guo, Bo Zhang, Xia Xue, et al.
Diabetes, Obesity & Metabolism|December 17, 2023
Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 2 trialYijun Li, Zhifeng Cheng, Weiping Lu, et al.
JAMA Network Open|August 19, 2024
GABA Analogue HSK16149 in Chinese Patients With Diabetic Peripheral Neuropathic Pain: A Phase 3 Randomized Clinical TrialXiaohui Guo, Tingting Zhang, Geheng Yuan, et al.
International Journal of Rheumatic Diseases|July 22, 2025
Clinical Practice Consensus Statement 2025: Management of Hyperuricemia and Gout in AdolescentsChanggui Li, Jie Lu, Zhaohui Lyu, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 9, 2025
RhTSH in aiding dynamic assessment in patients with differentiated thyroid CancerYanSong Lin, Qiang Wen, Wei Fu, et al.
Diabetes Care|November 9, 2023
Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 TrialBo Zhang, Zhifeng Cheng, Ji Chen, et al.
The Lancet. Diabetes & Endocrinology|August 25, 2025
Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trialYang He, Nianrong Mi, Zhifeng Cheng, et al.
Pain and Therapy|May 16, 2025
Rapid Onset of Pain Relief with Crisugabalin in Patients with Diabetic Peripheral Neuropathic Pain: Findings from a Multicenter, Randomized, Double-Blind, Controlled StudyTianrong Pan, Jianhua Ma, Yukun Li, et al.
International Journal of Rheumatic Diseases|July 22, 2025
2024 Update of Chinese Guidelines for Diagnosis and Treatment of Hyperuricemia and Gout Part I: Recommendations for General PatientsMingshu Sun, Zhaohui Lyu, Can Wang, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Nature|December 17, 2025
Mazdutide versus placebo in Chinese adults with type 2 diabetesDalong Zhu, Jiajun Zhao, Hanqing Cai, et al.
Nature|December 17, 2025
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetesLixin Guo, Bo Zhang, Xia Xue, et al.
Diabetes, Obesity & Metabolism|December 17, 2023
Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 2 trialYijun Li, Zhifeng Cheng, Weiping Lu, et al.
JAMA Network Open|August 19, 2024
GABA Analogue HSK16149 in Chinese Patients With Diabetic Peripheral Neuropathic Pain: A Phase 3 Randomized Clinical TrialXiaohui Guo, Tingting Zhang, Geheng Yuan, et al.
International Journal of Rheumatic Diseases|July 22, 2025
Clinical Practice Consensus Statement 2025: Management of Hyperuricemia and Gout in AdolescentsChanggui Li, Jie Lu, Zhaohui Lyu, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 9, 2025
RhTSH in aiding dynamic assessment in patients with differentiated thyroid CancerYanSong Lin, Qiang Wen, Wei Fu, et al.
Diabetes Care|November 9, 2023
Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 TrialBo Zhang, Zhifeng Cheng, Ji Chen, et al.
The Lancet. Diabetes & Endocrinology|August 25, 2025
Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trialYang He, Nianrong Mi, Zhifeng Cheng, et al.
Pain and Therapy|May 16, 2025
Rapid Onset of Pain Relief with Crisugabalin in Patients with Diabetic Peripheral Neuropathic Pain: Findings from a Multicenter, Randomized, Double-Blind, Controlled StudyTianrong Pan, Jianhua Ma, Yukun Li, et al.
International Journal of Rheumatic Diseases|July 22, 2025
2024 Update of Chinese Guidelines for Diagnosis and Treatment of Hyperuricemia and Gout Part I: Recommendations for General PatientsMingshu Sun, Zhaohui Lyu, Can Wang, et al.
Pageof 8